Aurélien Marabelle
Aurélien Marabelle is the immunotherapy investigator behind the tumour-agnostic pembrolizumab data in MSI-high cancers.
Aurélien Marabelle leads early-phase immunotherapy at Gustave Roussy's DITEP. He was lead author of the KEYNOTE-158 analysis that supported pembrolizumab's tumour-agnostic approvals and works on intratumoural immunotherapy.
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-177
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors.
- TrialKEYNOTE-006
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors.
- Key paperLe 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ
Shares Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1, Pembrolizumab.
- TermImmuno-oncology (IO) and checkpoint blockade
Shares Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Pembrolizumab, Immune checkpoint inhibitors.
- PersonFabrice Barlesi
- Key paperKEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer
Shares Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1, Pembrolizumab.
- Key paperLe 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval
Shares Tumour mutational burden (TMB), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), PD-1, Pembrolizumab.